<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-0432</issn>
        <issn pub-type="epub">1557-3265</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC11096044</article-id>
        <article-id pub-id-type="pmcid-ver">PMC11096044.319</article-id>
        <article-id pub-id-type="pmcaid">11096044</article-id>
        <article-id pub-id-type="pmcaiid">11096044</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1979611</article-id>
        <article-id pub-id-type="pmid">38488807</article-id>
        <article-id pub-id-type="doi">10.1158/1078-0432.CCR-24-0148</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1979611</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1979611</article-id>
        <article-version article-version-type="pmc-version">319</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Dermawan</surname>
              <given-names initials="JK">Josephine K.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chiang</surname>
              <given-names initials="S">Sarah</given-names>
            </name>
            <xref rid="A2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Singer</surname>
              <given-names initials="S">Samuel</given-names>
            </name>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jadeja</surname>
              <given-names initials="B">Bhumika</given-names>
            </name>
            <xref rid="A3" ref-type="aff">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hensley</surname>
              <given-names initials="ML">Martee L.</given-names>
            </name>
            <xref rid="A4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Tap</surname>
              <given-names initials="WD">William D.</given-names>
            </name>
            <xref rid="A4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Movva</surname>
              <given-names initials="S">Sujana</given-names>
            </name>
            <xref rid="A4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Maki</surname>
              <given-names initials="RG">Robert G</given-names>
            </name>
            <xref rid="A4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Antonescu</surname>
              <given-names initials="CR">Cristina R</given-names>
            </name>
            <xref rid="A2" ref-type="aff">2</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Division of Pathology, Diagnostics Institute, Cleveland Clinic, Cleveland, OH, USA.</aff>
        <aff id="A2"><label>2</label>Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A3"><label>3</label>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A4"><label>4</label>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.</aff>
        <author-notes>
          <fn fn-type="con" id="FN1">
            <p id="P1">Authors’ Contributions</p>
            <p id="P2">JKD: conceptualization, data curation, formal analysis, data interpretation, writing and revision of the paper. SC, SS, BJ, MLH, WDT, SM, RGM: data curation, review and editing. CRA: study design and conception, data curation, analysis and interpretation of data, writing, reviewing and revision of paper. All authors read and approved the final manuscript.</p>
          </fn>
          <corresp id="CR1"><bold>Correspondence:</bold> Cristina R. Antonescu, MD, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, <email>antonesc@mskcc.org</email></corresp>
        </author-notes>
        <pub-date pub-type="ppub">
          <day>15</day>
          <month>5</month>
          <year>2024</year>
        </pub-date>
        <volume>30</volume>
        <issue>10</issue>
        <issue-id pub-id-type="pmc-issue-id">462432</issue-id>
        <fpage>2260</fpage>
        <lpage>2271</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>04</day>
              <month>04</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>15</day>
              <month>11</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>15</day>
              <month>11</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-11-15 00:25:25.123">
              <day>15</day>
              <month>11</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1979611.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Purpose:</title>
            <p id="P3">Leiomyosarcomas (LMS) are clinically and molecularly heterogeneous tumors. Despite recent large scale genomic studies, current LMS risk stratification is not informed by molecular alterations. We propose a clinically applicable genomic risk stratification model.</p>
          </sec>
          <sec id="S2">
            <title>Experimental Design:</title>
            <p id="P4">We performed comprehensive genomic profiling in a cohort of 195 soft tissue LMS (STLMS), 151 primary at presentation, and a control group of 238 uterine LMS (ULMS), 177 primary at presentation, with at least one-year follow up.</p>
          </sec>
          <sec id="S3">
            <title>Results:</title>
            <p id="P5">In STLMS, FNCLCC grade but not tumor size predicted progression-free survival (PFS) or disease-specific survival (DSS). In contrast, in ULMS, tumor size, mitotic rate and necrosis were associated with inferior PFS and DSS. In STLMS, a 3-tier genomic risk stratification performed well for DSS: high risk – co-occurrence of <italic toggle="yes">RB1</italic> mutation and chr12q deletion (del12q)/<italic toggle="yes">ATRX</italic> mutation; intermediate risk – presence of <italic toggle="yes">RB1</italic> mutation, <italic toggle="yes">ATRX</italic> mutation or del12q; low risk – lack of any of these three alterations. The ability of <italic toggle="yes">RB1</italic> and <italic toggle="yes">ATRX</italic> alterations to stratify STLMS was validated in an external AACR GENIE cohort. In ULMS, a 3-tier genomic risk stratification was significant for both PFS and DSS: high risk – concurrent <italic toggle="yes">TP53</italic> mutation and chr20q amplification/<italic toggle="yes">ATRX</italic> mutations; intermediate risk – presence of <italic toggle="yes">TP53</italic> mutation, <italic toggle="yes">ATRX</italic> mutation or amp20q; low risk – lack of any of these three alterations. Longitudinal sequencing showed that most molecular alterations were early clonal events that persisted during disease progression.</p>
          </sec>
          <sec id="S4">
            <title>Conclusions:</title>
            <p id="P6">Compared to traditional clinicopathologic models, genomic risk stratification demonstrates superior prediction of clinical outcome in STLMS and is comparable in ULMS.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>leiomyosarcoma</kwd>
          <kwd>genomic risk</kwd>
          <kwd>nomogram</kwd>
          <kwd>soft tissue</kwd>
          <kwd>uterine</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
